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Abstract
Background: Glucocorticoid-mediated inhibition of angiogenesis is important in physiology, pathophysiology and therapy.
However, the mechanisms through which glucocorticoids inhibit growth of new blood vessels have not been established.
This study addresses the hypothesis that physiological levels of glucocorticoids inhibit angiogenesis by directly preventing
tube formation by endothelial cells.
Methodology/Principal Findings: Cultured human umbilical vein (HUVEC) and aortic (HAoEC) endothelial cells were used
to determine the influence of glucocorticoids on tube-like structure (TLS) formation, and on cellular proliferation (5-bromo-
29-deoxyuridine (BrdU) incorporation), viability (ATP production) and migration (Boyden chambers). Dexamethasone or
cortisol (at physiological concentrations) inhibited both basal and prostaglandin F2a (PGF2a)-induced and vascular
endothelial growth factor (VEGF) stimulated TLS formation in endothelial cells (ECs) cultured on Matrigel, effects which were
blocked with the glucocorticoid receptor antagonist RU38486. Glucocorticoids had no effect on EC viability, migration or
proliferation. Time-lapse imaging showed that cortisol blocked VEGF-stimulated cytoskeletal reorganisation and
initialisation of tube formation. Real time PCR suggested that increased expression of thrombospodin-1 contributed to
glucocorticoid-mediated inhibition of TLS formation.
Conclusions/Significance: We conclude that glucocorticoids interact directly with glucocorticoid receptors on vascular ECs
to inhibit TLS formation. This action, which was conserved in ECs from two distinct vascular territories, was due to
alterations in cell morphology rather than inhibition of EC viability, migration or proliferation and may be mediated in part
by induction of thrombospodin-1. These findings provide important insights into the anti-angiogenic action of endogenous
glucocorticoids in health and disease.
Citation: Logie JJ, Ali S, Marshall KM, Heck MMS, Walker BR, et al. (2010) Glucocorticoid-Mediated Inhibition of Angiogenic Changes in Human Endothelial Cells Is
Not Caused by Reductions in Cell Proliferation or Migration. PLoS ONE 5(12): e14476. doi:10.1371/journal.pone.0014476
Editor: Pieter H. Reitsma, Leiden University Medical Center, Netherlands
Received April 27, 2010; Accepted November 10, 2010; Published December 31, 2010
Copyright:  2010 Logie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JJL was funded by a Medical Research Council studentship and KMM was funded by a postdoctoral fellowship from Medical Research Scotland. MMSH
is a Wellcome Trust University Award holder. PWFH and BRW are funded by the British Heart Foundation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: phadoke@staffmail.ed.ac.uk
Introduction
The well-documented ability of glucocorticoids to inhibit
angiogenesis [1] is exploited clinically for the reduction of
proliferating capillary haemangiomas [2] and may have potential
in treatment of some cancers. For example, exposure of prostate
cancer cells to dexamethasone caused a glucocorticoid receptor
(GR)-dependent down-regulation of pro-angiogenic factor (vascu-
lar endothelial growth factor, VEGF; interleukin-8, IL-8) gener-
ation and reduced the size and microvessel density of tumour
xenografts [3]. There is also increasing evidence that endogenous
glucocorticoids contribute to regulation of new vessel formation
(reviewed in [4]). Suppression of angiogenesis may contribute to
impaired wound healing in glucocorticoid excess [5] whilst pre-
receptor regulation of glucocorticoid concentrations in target
tissues (by the isozymes of 11b-hydroxysteroid dehydrogenase;
11b-HSD) has been linked to both physiological and pathophys-
iological angiogenesis. In the human reproductive tract abnormal
inactivation of cortisol by 11b-HSD type 2 may contribute to the
dysregulation of angiogenesis associated with heavy menstrual
bleeding [6]. Conversely, generation of glucocorticoids by 11b-
HSD type 1 has been shown to inhibit recovery from cutaneous
wounds and myocardial infarction [7], and increase age-related
bone fragility [8] by suppressing angiogenesis.
Surprisingly, despite the extensive use of glucocorticoids as
positive controls in many studies of angiogenesis, the mechanisms
whereby these steroids inhibit new vessel formation remain
unclear. In some cases, inhibition of angiogenesis has been linked
to suppression of angiogenic factor generation by cells neighbour-
ing the vasculature [3;9]. However, glucocorticoids can directly
inhibit tube formation by cultured endothelial cells (EC; [6]). It has
not been established whether this is due to the ability of
glucocorticoids to inhibit the proliferation, migration and/or
remodelling of endothelial cells (which have a central role in
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eration [11–13] and migration [14] of vascular smooth muscle
cells, a similar effect on endothelial cells seems likely. Indeed, the
endothelium is a likely target for glucocorticoids as it expresses
both glucocorticoid (GR) and mineralocorticoid receptors [15;16].
Furthermore, inhibition of cell protease activity by angiostatic
steroids [17] suggests, indirectly, that glucocorticoids inhibit EC
migration (since extra-cellular matrix (ECM) degradation is
required for cell motility in vivo). There is also evidence that
glucocorticoids inhibit EC migration in the microvasculature
without altering proliferation or viability [18].
Therefore, this investigation built on our previous demonstration
[7] that glucocorticoids inhibitangiogenesis in vitro (mouse aorticring
in Matrigel), in vivo (sub-cutaneous sponge implantation) and during
wound healing (following cutaneous incision or myocardial infarc-
tion) to explore the hypothesis that this action of glucocorticoids is
due to the direct prevention of tube formation by endothelial cells.
Complementary in vitro techniques were used to determine whether
anti-angiogenic effects of glucocorticoids could be attributed to
inhibition of endothelial cell viability, migration or proliferation.
Materials and Methods
Steroids and drugs
Unless otherwise stated, chemicals, reagents and drugs were
obtained from Sigma, Dorset, UK. Enzymes for molecular biology
were from Promega, Southampton, UK.
Endothelial cell culture
Primary human umbilical vein ECs (HUVECs) and human aortic
ECs (HAoECs) (Promocell, Heidelberg, Germany) were cultured
(37uC, 5% CO2) in EC growth medium-2 (EGM-2) consisting of EC
basal medium supplemented with 2% fetal bovine serum, gentami-
cin/amphotericin (GA-1000), and growth supplements (Lonza,
Wokingham, UK). All ECs were studied between passages 2 and 6.
Tube-like structure (TLS) formation
HUVECs and HAoECs (4610
4 cells/well) were re-suspended in
basal medium (1 ml) and seeded onto 24 well plates coated with
Matrigel (250 ml, BD Biosciences, Oxford, UK) as described
[19;20]. Basal medium comprised EGM-2 supplemented with
ascorbic acid, heparin and GA-1000 but without serum or growth
factors. Drugs, growth factors or vehicle control (0.004% ethanol
v/v) were added at the start of each experiment at concentrations
indicated in Figure legends.
Photomicrographs (56magnification) of the centre of each well
were obtained after incubation for 4, 8 and 24 hours [21] and
TLSs were quantified by counting branch points by an investigator
blinded to treatment. Data were expressed as a percentage of the
number of connections in control wells.
TLS formation was assessed directly using time-lapse imaging.
HUVECs (2610
5)i n2m lb a s a lm e d i u mc o n t a i n i n g5m MH E P E S
(Lonza, UK) were seeded onto SlideFlasks (Nunc, New York, USA)
pre-coated with 750 ml Matrigel and incubated with vehicle or 10 ng/
ml VEGF, 600 nM cortisol, or both. Images were acquired with a
Leica DM IRBE microscope (106 magnification) and Q500MC
image processing system (Leica Cambridge Ltd, UK) from 3 separate
positions/flask every 4 minutes for 24 hours. Tubes per field of view
were counted every 2 hours in reconstructed movie clips.
Immunohistological charactisation of TLSs
The endothelial nature of TLSs was assessed using immuno-
histochemistry. Briefly, HUVECs (10,000) were cultured in
standard basal medium (250 ml; 5 hours) on 8-well permanox
chamber slides (Nunc, USA) pre-coated with Matrigel (100 ml).
TLSs were fixed in 10% formalin and stained using the Vectastain
ABC Kit (Vector Laboratories, USA), according to the manufac-
turer’s instructions, in combination with rat anti-mouse CD31 (1
in 50 dilution) monoclonal antibody (BD Pharmingen, USA).
Slides were incubated (room temperature; 5 minutes) with 3,39-
diaminobenzidine (DAB) (Vector Laboratories, USA) with positive
structures staining brown. For negative controls, the primary
antibody was omitted. Slides were viewed by light microscopy
(Karl Zeiss Axioskop, Carl Zeiss MicroImaging, Inc, USA) and
images captured from a live-feed camera (3-CCD, JVC Profes-
sional Europe Ltd, UK) using the Microcomputer Imaging Device
(MCID; InterFocus Imaging Ltd, UK).
Staining of HUVEC cytoskeleton
Components of the EC cytoskeleton under basal conditions and
during TLS formation were assessed using immunofluorescent
staining. Briefly, HUVECs were re-suspended in EGM-2 basal
medium growth medium with or without cortisol (600 nM), and
seeded onto coverslips coated with phenol red-free Matrigel (30 ml).
After incubation for 1, 4, 10 or 22 hours, cells were fixed,
permeabilised and blocked [22], then incubated with mouse
monoclonal anti-a-tubulin antibody (clone B512, Sigma; 1:1000,
1 hour). Secondary goat anti-mouse IgG (H+L, Alexa Fluor 594,
Molecular Probes-Invitrogen, Paisley, UK; 1:500) was then added
for 1 hour. Direct fluorescent labelling of filamentous-actin (F-actin)
and DNA was achieved by including (1:500) phalloidin Alexa Fluor
488 (Molecular Probes-Invitrogen) or DAPI (0.1 mg/ml), respec-
tively, with the secondary antibody. Coverslips were mounted on
slides with Mowiol-glycerol and imaged as described [22].
mRNA isolation and identification
ECs or TLSs grown on Matrigel were recovered using
MatriSperse cell recovery solution (BD Biosciences, Oxford, UK)
according to manufacturer’s instructions. RNA was isolated using
TRIzol (Invitrogen Life Technologies, Paisley, UK) and quantified
with UV spectroscopy. mRNA for GR was assessed in confluent
ECs and established TLSs. Total RNA (1 mg) was reverse-
transcribed (45 min, 42uC) using a Kit (Promega, Southampton,
UK). cDNA templates underwent PCR amplification (35 cycles)
with Taq polymerase in the presence of oligonucleotides specific
for GR (59-GTGGTTTATAGAGGGCCAAGACTTGG-39 and
59-GGCACAACTTCCCTTTTCTGATATACAC-39). PCR was
performed as described [23] with an annealing temperature of
62uC. Products were analyzed by electrophoresis (1.2% agarose
gel w/v in TBE buffer containing 0.001% ethidium bromide v/v)
and visualized under UV light. PCR product size was 354 base
pairs (bp). Negative controls included either no reverse transcrip-
tase, or no cDNA template.
Quantitative real-time PCR (QrtPCR)
The influence of glucocorticoids on the expression of angiogenic
factors during TLS formation was examined using quantitative
real-time PCR (QrtPCR). HUVECs (100,000/ml) were seeded on
Matrigel-coated cell culture dishes in the presence of cortisol
(600 nM) or vehicle (control) and incubated for 1, 4, 8 or 22 hours.
RNA was recovered using Matrisperse solution, Trizol (1 ml) was
added to the cell pellet and the sample was frozen (280uC).
cDNA was synthesised from RNA using the Promega Reverse
Transcription System (Promega UK, Southampton, UK). The
reactions were carried out on an Eppendorf Mastercycler Gradient
(Eppendorf, Germany) consisting of incubation at 42uC for 45
minutes followed by 95uC for 5 minutes and finally chilled to 4uC.
Quantification of the transcript was performed using human
GR and Angiogenesis
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use assays (Applied Biosystems, Cheshire, UK) with the Light-
cycler 480 Real Time PCR system (Roche Diagnostics Ltd, West
Sussex, UK). Samples were heated to 95uC for 5 minutes for pre-
incubation then underwent 50 cycles of PCR amplification
(denaturation at 95uC for 10 seconds, primer annealing at 60uC
for 30 seconds and elongation at 72uC for 1 second) and finally
underwent cooling at 40uC for a further 5 minutes.
RNA levels were determined for each sample, run in triplicate,
from standard curves generated for each primer-probe set by serial
dilution of pooled cDNA from each tissue. Cyclophylin
(Mm02342430_g1; Applied Biosystems, Cheshire, UK) mRNA
levels were used as internal references to normalise transcript
levels. Changes in mRNA levels in TLS exposed to cortisol were
determined for genes involved with stimulation of angiogenesis
(VEGF, VEGFR2), inhibition of angiogenesis (thrombospondin-1),
cell-matrix interactions (m6-integrin, caveolin-1) and regulation of
cell fate (delta-like-4 (Dll4), Notch).
Endothelial cell viability
ATP production was measured from viable cells (Cell Titer Glo
assay, Promega, UK). HUVECs (1.5610
3 cells/well) were seeded
onto plates for 2 hours, then incubated for 94 hours as described
for BrdU. CellTiter-Glo Reagent (100 ml) was then added to each
well (10 minutes, room temperature) before detection of
luminescence (Wallac 1420 VICTOR
2 plate reader, Perkin-
Elmer, Buckinghamshire, UK).
Endothelial cell proliferation
To perform BrdU incorporation assays (Calbiochem-Merck,
Nottingham, UK), HUVECs (3.5610
3 cells/well) were cultured in
growth medium (EGM-2 basal medium (Lonza, UK) supplemented
with heparin, ascorbic acid, GA-1000, and 2% charcoal-stripped
fetal bovine serum) without additional growth factors, and then
incubated for 46 hours with: VEGF (25 ng/ml); VEGF plus
SU5416 (1 nM-1 mM); VEGF plus cortisol (3 nM-1 mM); vehicle
(0.004% ethanol v/v or 0.167% DMSO v/v); or medium alone.
BrdU was added to the wells 1 hour after incubations started. After
further incubation (45 hours), cells were fixed, denatured (BrdU
assay kit, manufacturer’s instructions), and incubated with the anti-
BrdU antibody and then with horseradish peroxidase-conjugated
secondary goat anti-mouse IgG. Finally, cells were incubated with
tetra-methylbenzidine (TMB) and the reaction stopped with
sulphuric acid (2.5 M). Optical densities (405 nm and 540 nm)
were measured (Multiskan Ascent plate reader, Cheshire, UK) and
the absorbance of cells without BrdU subtracted from each reading.
Endothelial cell migration
Boyden chambers [24] were prepared by seeding HUVECs
(2610
5) onto the upper compartment of 8.0 mm ThinCerts
(Greiner Bio-One, Gloucestershire, UK), incubating (24 hours,
37uC), and then labelling with calcein-AM (8 mM). Labelled cells
were detached (Trypsin-EDTA) from the underside of ThinCerts
and fluorescence measured (Fluoroskan Ascent FL plate reader,
Cheshire, UK). The influence of cortisol on migration was assessed
by adding VEGF (10 ng/ml), VEGF plus the tyrosine kinase
inhibitor SU5416 (1 mM; which inhibits the angiogenic signalling
induced by VEGF binding to its receptor), VEGF plus cortisol
(600 nM), SU5416 alone or cortisol alone to the medium.
Statistics
Results from triplicate wells in the same experiment were
averaged and treated as single data points. Data are expressed as
mean6SEM, where n indicates the number of experiments.
Statistical analysis was performed by one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison post hoc test
or by repeated measures ANOVA. Differences were considered
significant when p,0.05.
Results
TLS formed by HUVECs retain an EC phenotype
HUVECs cultured on plastic retained a typical cobblestone
appearance (not shown). Once cultured on Matrigel, however,
they formed characteristic networks of tube-like structures. These
comprised cells connected by filopodia-like extensions which
retained immunoreactivity for CD31 (an endothelial cell marker;
Figure 1A). At higher magnification these cell-cell connections
showed evidence of lumen formation. (Figure 1A).
Characterisation of cells forming TLSs
Staining of actin filaments (with fluorescently-conjugated
phalloidin) and microtubules (with a-tubulin antibodies) clearly
identified cytoskeletal fibres in undifferentiated HUVECs
(Figure 1B; n=4). Actin filaments appeared as well-formed,
parallel stress fibres throughout the cytoplasm while microtubules
appeared to radiate from the centrosome region occupying the
traditional peri-nuclear area. F-actin appeared more diffuse and
homogeneous throughout cells after 1 hour of cortisol treatment,
while microtubule staining appeared unaffected (Figure 1B, n=2).
Microtubules and actin filaments were both observed in TLSs
formed after 4 hours on Matrigel (not shown) and remained
evident after 8 (not shown), 10 and 22 hours in culture (Figure 1B).
GR expression in EC monolayers and following formation
of TLS by HUVECs
Expression of GR was demonstrated in confluent HUVECs and
HAoECs (Figure 1C), and was maintained in HUVECs 22 hours
after induction of TLS formation (Figure 1C).
Cortisol evokes a GR-mediated inhibition of TLS
formation
TLS formation by HUVECs was inhibited by cortisol (300–
1200 nM; Figure 2A–B), but not by cortisone (the inert 11-keto
metabolite of cortisol, 300–1200 nM; Figure 2A–B), in a
concentration- and time-dependent manner. This inhibition was
abolished by the GR antagonist RU38486 (Figure 2C). Inhibition
of TLS formation was also obtained with the GR selective,
synthetic glucocorticoid dexamethasone (600 nM; Figure 2C).
Similar results were obtained in HAoECs in which inhibition of
TLS formation by both cortisol and dexamethasone was evident
after 5 hours (Figure 3A(i)) and maintained after 22–24 hours
(Figure 3A(ii)) in culture.
VEGF stimulated TLS formation both by HAoECs (Figure 3B)
and by HUVECs (Figure 4). This effect was blocked in both cell
types by cortisol and dexamethasone (p,0.01) after 4 hours (data
not shown) and 22–24 hours (Figures 3 & 4) in culture. PGF2a
(100 nM) also stimulated TLS formation by HUVECs (13869%
connections relative to control, p,0.01) and this effect was blocked
by 600 nM cortisol (10568% connections, p,0.05 compared with
PGF2a alone) after 5 hours.
Time-lapse imaging of HUVECs cultured on Matrigel revealed
minimal cell migration or proliferation, with TLS formation
consisting mainly of cell stretching to facilitate connection between
adjacent cells. TLS generation began almost immediately after
seeding cells on Matrigel, and peaked after approximately 8 hours
GR and Angiogenesis
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14476Figure 1. Formation of tube-like structures (TLS) and expression of glucocorticoid receptors (GR) in human endothelial cells. (A)
Human umbilical vein endothelial cells (HUVECs) cultured on Matrigel formed a network of tube-like structures (TLSs), after approximately 4 hrs, that
retained immunoreactivity for the endothelial cell marker CD31 (original magnification 610). At higher magnification, cell membranes were evident
(arrow head), suggesting development of a lumen in the cell-cell connections (original magnification 640). No staining was observed in negative
controls lacking primary antibody. (B) HUVECs cultured on uncoated cover slips showed clearly-defined cytoskeletal components: filamentous (F)-
actin (stained with phalloidin-488; green) and a-tubulin (stained with goat anti-mouse IgG Alexa Fluor 594 secondary antibody; red), and nucleus
(DNA stained with 49,6-diamidino-2-phenylindole dihydrochloride (DAPI); blue). Exposure to cortisol (600 nM; 1 hour) had no apparent effect on
microtubule staining but induced a more diffuse and homogeneous distribution of F-actin throughout cell. TLSs stained after 10 hours or 22 hours in
culture, consisted of adjoining, filopodia-like extensions, containing both F-actin (green) and a-tubulin (red), connecting neighbouring cells (DNA,
blue). (C) GR were detected both in first passage (P1) human umbilical vein (HUVECs) and in passaged human aortic (HAoECs) endothelial cells (P2–
GR and Angiogenesis
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cells had detached after 24 hours. Cortisol (600 nM) reduced TLS
formation (Figure 4B), whereas VEGF (10 ng/ml) stimulated TLS
formation and this effect was blocked by cortisol (600 nM). These
observations were confirmed by comparison of the time taken to
achieve maximum tube formation (Figure 4C).
Influence of cortisol on endothelial cell migration,
proliferation and viability
The impact of exposure to cortisol on cell viability was tested by
measuring ATP production. Exposure to VEGF increased ATP
production by HUVECs. ATP production was inhibited in a
concentration-dependent manner by SU5416 (1 nM-1 mM) but
not by cortisol (3 nM–1 mM) (Figure 5A). Cell proliferation was
measured using BrdU incorporation. Exposure to cortisol (3 nM-
1 mM) did not alter the VEGF-induced increase in BrdU
incorporation whereas SU5416 (1 nM–1 mM) produced a con-
centration-dependent inhibition (Figure 5B). Migration of HU-
VECs was assessed using a modified Boyden chamber assay. The
EC50 (10 ng/ml) for VEGF-stimulated HUVEC migration was
established in pilot investigations (not shown). VEGF-induced
migration was abolished by exposure to SU5416 whereas cortisol
(600 nM) had no effect on either basal or VEGF-induced
migration (Figure 5C).
Influence of cortisol on gene expression of potential
modulators of angiogenesis in HUVECs
QrtPCR measurements indicated gene expression varied with
time during TLS development but that cortisol did not alter
mRNA levels of VEGF (Figure 6A) or VEGF-R2 (Figure 6B).
Similarly cortisol had no effect on Dll-4, notch-1, a6-integrin
or caveolin-1 (not shown). In contrast cortisol produced a
significant (p,0.05) 2.3-fold increase in thromobospondin-1
mRNA level in TLSs after (but not 1, 4 or 22) 8 hours
incubation (Figure 6C).
Discussion
This investigation addressed the hypothesis that the potent anti-
angiogenic action of glucocorticoids is due to prevention of tube
formation by endothelial cells. These results show that glucocor-
ticoids do indeed induce direct, GR-mediated inhibition of tube
formation by primary human ECs. Application of time-lapse
imaging clearly demonstrated that TLS formation by ECs cultured
on Matrigel required extension of filopodia and formation of
connections with minimal EC proliferation or migration. Exposure
to glucocorticoids reduced the formation of cell-cell contacts rather
than increasing degradation of existing tubes. Consistent with this
mode of action, glucocorticoid exposure did not measurably
impair EC proliferation, migration or viability. Furthermore,
glucocorticoids inhibited basal, and VEGF- or PGF2a-stimulated,
angiogenesis, suggesting that they act by inhibiting the final
common pathway which initiates tube formation. The majority of
experiments used human umbilical vein endothelial cells, which
provide a useful and readily available source of cells. However, key
results were recapitulated using human aortic endothelial cells,
demonstrating that the actions of glucocorticoids were not
restricted to a single type of endothelial cell, but are likely to be
relevant to ECs located throughout the systemic circulation.
Previous investigations suggest that glucocorticoids inhibit
angiogenesis by inhibiting VEGF [25–28] and/or prostaglandin
[29–31] production. In the present study we found that
glucocorticoids blocked basal, VEGF-induced, and PGF2a-
induced, TLS formation. It may be that basal TLS formation in
Figure 2. Cortisol, not cortisone, induces glucocorticoid
receptor-dependent inhibition of TLS formation by human
umbilical endothelial cells. Compared with controls, cortisol, but
not cortisone, (300–1200 nM) reduced tube-like structure (TLS)
formation by human umbilical vein endothelial cells (HUVECs) after
5 hours in culture (A), an effect which achieved significance after 22–
24 hours (B). The glucocorticoid receptor (GR)-selective steroid dexa-
methasone (600 nM) produced a similar reduction in TLS formation
whilst the response to cortisol was abolished by GR antagonism with
RU38486 (1 mM) (C). Data represent mean6standard error of mean
(SEM) (n=3–6, each condition performed in triplicate) and were
analysed using one-way analysis of variance (ANOVA) and Dunnett’s
post hoc test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0014476.g002
P4), by RT-PCR (354 bp product). GR expression was maintained in HUVECs 22 hours after TLS formation. L, Liver (positive control). Negative controls
included no reverse transcriptase and no cDNA (not shown).
doi:10.1371/journal.pone.0014476.g001
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the Matrigel and/or the ECs. In this way glucocorticoids could be
interfering with either VEGF or prostanoids under basal
conditions, as well as after addition of growth factors. Since
VEGF and PGF2a stimulate angiogenesis through discrete second
messenger pathways (phospholipase Cc-Ras-Raf [32] and cyclic
adenosine monophosphate (cAMP)-inositol trisphosphate [33],
respectively), it appears likely that glucocorticoids influence a final
common pathway (e.g. extracellular signal-regulated kinase-mito-
gen activated protein kinase (ERK-MAPK)) involving calcium
exchange and/or its downstream signalling effects. Therefore, we
explored ‘downstream’ effects on cell morphology, migration and
proliferation.
Few previous studies have investigated the effects of glucocor-
ticoids on EC biology in vitro. Those that are available have
generally used pharmacological concentrations of synthetic
glucocorticoids [34] or ECs of non-human origin [35]. The
receptor responsible for angiostatic effects of corticosteroids has
Figure 3. Cortisol and dexamethasone inhibit basal and stimulated TLS formation in human aortic endothelial cells. (A) Cortisol
(600 nM) and dexamethasone (600 nM) inhibited basal tube-like structure (TLS) formation of human aortic endothelial cells (HAoEC) after (i) 5 hr and
(ii) 22–24 hour treatment. (B) Similarly, growth factor (VEGF)-induced TLS formation by HAoECs was also inhibited after 22–24 hours exposure to
cortisol or Dex. Data represent mean6standard error of mean (SEM) (n=5, each exposure performed in triplicate) and were analysed by one-way
analysis of variance (ANOVA) and Dunnett’s post hoc test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0014476.g003
GR and Angiogenesis
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have both been demonstrated previously in HUVECs [36;37], but
neither receptor has been identified in HAoECs. We used a
qualitative approach to show that the GR receptor is present in
HUVECs and in HAoECs. The ability of the GR-selective steroid
dexamethasone to inhibit TLS formation, combined with the
Figure 4. Glucocorticoids reduce formation and stability of TLSs formed by human umbilical vein endothelial cells grown on
Matrigel. TLS formation by human umbilical vein endothelial cells (HUVECs) was quantified using time-lapse video microscopy. (A)Tube-like structures
(TLS) formation (solid arrows) occurred rapidly (0–4 hours) after seeding, stabilised (4–8 hours) and was followed by degradation and detachment (8–
24 hours). (B) Cortisol (600 nM) reduced TLS formation (0–4 hours) and TLS stability (2–4 hours). Exposure to vascular endothelial growth factor (VEGF,
10 ng/ml) increased and accelerated TLS formation but did not influence TLS stability. This effect of VEGF was abolished by co-incubation with cortisol
(600 nM)(**p,0.01 byrepeatedmeasuresanalysisofvariance(ANOVA)).(C)TheratetomaximumTLS developmentwas increasedbyVEGF(*p,0.05by
one-way ANOVA and Dunnett’s post hoc test) and this effect was blocked by cortisol. Data represent mean6standard error of mean (SEM) (n=6).
doi:10.1371/journal.pone.0014476.g004
GR and Angiogenesis
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(RU38486), indicates that glucocorticoids directly inhibit TLS
formation by activation of GR.
Using time-lapse imaging to examine the dynamic nature of
TLS formation indicated that, consistent with other endothelial
tube formation models [38;39], cell proliferation and migration
play little role in TLS development in vitro. HUVEC viability
was not reduced by increasing concentrations of cortisol,
indicating that reduced TLS generation is not the result of a
toxic effect on ECs. Moreover, we demonstrated that glucocor-
ticoids do not measurably inhibit migration or proliferation of
HUVECs. The ability of glucocorticoids to inhibit EC migration
has not been assessed before but has been inferred from the
inhibitory action of angiostatic steroids on protease activity [40].
Glucocorticoid-mediated inhibition of proliferation has been
demonstrated in rat and bovine smooth muscle cells [11–13] but
previously reported effects on ECs are inconsistent: high
concentrations of synthetic corticosteroid inhibit human EC
proliferation in vitro [41–43] but dexamethasone (10
210–
10
25 M) had no effect on bovine corneal EC proliferation
[44]. The lack of effect of cortisol in the proliferation assay
(Figure 5B) is supported by data generated by time-lapse
imaging with direct observation of endothelial cell proliferation
which showed that proliferation is not a key component of TLS
f o r m a t i o ni nt h i sm o d e l .
Time-lapse imaging also revealed that formation of TLSs
occurred via the development and connection of filopodia-like
extensions between adjacent cells and that cortisol inhibits
initial formation of tubes, rather than accelerating their
degradation. Imaging of the cytoskeleton in HUVECs support-
ed this hypothesis, demonstrating that the arrangement of F-
actin, but not a-tubulin, became rapidly disorganised in cells
treated with cortisol. Dexamethasone-mediated alterations in
the cytoskeleton have been reported previously in EC mono-
layers (40) and it is known that interfering with microfilaments
or microtubules suppresses key angiogenic responses (41).
These results suggest that glucocorticoids may alter EC
morphology or the ability of endothelial cells to interact with
one another through the establishment of productive cell-to-cell
connections. However, real time analysis of suggests that this is
not the only mechanism through which cortisol inhibits tube
formation.
The lack of effect of cortisol on Dll-4, notch, caveolin-1 and a6-
integrin suggests that increased expression of these factors does not
contribute to the GR-mediated inhibition of TLS formation.
Furthermore, although glucocorticoids decrease stimulated ex-
pression of VEGF (via GR) in some cells (including vascular
smooth muscle (24)), the current results suggest that (in the absence
of additional growth factors) reduced VEGF expression in
endothelial cells does not contribute to cortisol-mediated inhibition
of TLS formation. This is supported by the lack of effect of cortisol
on VEGF-R2 mRNA levels, which is consistent with a previous
study in cell monolayers [45]).
Indeed, of the factors examined, only TSP-1 mRNA was shown
to be regulated by cortisol. The magnitude of this induction was
similar to that produced by glucocorticoids, in trabecular
meshwork (TM) cells (which have similarities to vascular
endothelial cells; (43)). Since it is a recognised inhibitor of tube
formation (44, 45), it is conceivable that increased expression of
TSP-1 could contribute to the anti-angiogenic properties of
glucocorticoids. Certainly, GR-dependent regulation of TSP-1
mRNA synthesis and protein production has been reported (44).
In addition, our group has reported evidence that TSP-1
contributes to cortisol-mediated inhibition of angiogensis in
human uterine endothelial cells (6).
In summary, although the phenomenon of steroid-induced
inhibition of angiogenesis has been recognised for over 30 years, its
mechanism(s) of action remain(s) obscure [46]. The present study
indicates a direct, GR-dependent action on ECs, independent of
Figure 5. Cortisol does not inhibit human umbilical vein
endothelial cell migration, proliferation or viability. (A) Human
umbilical vein endothelial cell (HUVEC) viability was increased by VEGF
(25 ng/ml) and this effect was blocked in a concentration-dependent
manner by (1–1000 nM) SU51416 but not by (3–1000 nM) cortisol (B)
Similarly, VEGF (25 ng/ml)-stimulated proliferation of cultured HUVECs
was blocked in a concentration-dependent manner by (1–1000 nM)
SU51416 but not by (3–1000 nM) cortisol. (C) Vascular endothelial
growth factor (VEGF) (10 ng/ml; 24 hr 37uC)-stimulated migration of
(HUVECs) was abolished by (1 mM) SU51416 but not by (600 nM)
cortisol. Data represent mean6standard error of mean (SEM) (n=6,
each condition performed in triplicate); *p,0.05 and **p,0.01 analysed
by one-way analysis of variance (ANOVA) and Dunnett’s post hoc test.
doi:10.1371/journal.pone.0014476.g005
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14476the anti-inflammatory effects of glucocorticoids. Cortisol-mediated
inhibition of tube formation was shown to occur without a
measurable reduction in endothelial cell migration or prolifera-
tion. Investigations of into the mechanism of GR-mediated
inhibition of TLS formation suggest that alterations in cytoskeletal
structure and induction of anti-angiogenic TSP-1 contribute to this
process. Our results shed light on the mechanism(s) underlying
glucocorticoid-mediated inhibition of angiogenesis in subcutane-
ous sponge implants in vivo, and in wound healing following skin
incision or myocardial infarction [7], and strengthen the case for
pharmacological inhibition of glucocorticoid action in these
physiological conditions. Our previous demonstration of increased
angiogenesis in animals with genetic disruption of (the glucocor-
ticoid-generating enzyme) 11b-HSD1 (7) suggest that these in vitro
data obtained with concentrations of cortisol approaching high
physiological levels are relevant in vivo.
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Figure 6. Cortisol increases expression of thrombospondin 1, but not of VEGF or VEGF receptor 2 during tube-like structure
formation by HUVECs. Effects of cortisol (600 nM) on the expression of (A) vascular endothelial growth factor (VEGF), (B) vascular endothelial
growth factor receptor 2 (VEGFR2) and (C) thrombospondin-1 (TSP-1) during tube-like structure (TLS) development by human umbilical vein
endothelial cells (HUVECs). Cortisol (600 nM) added to the culture medium at time of cell seeding, did not alter expression of VEGF or VEGFR2
but transiently increased (*p,0.05) TSP-1 expression after 8 hours in culture. Quantitative real-time PCR (QrtPCR) measurements; were
expressed as a ratio of concentration of mRNA of gene of interest to internal control (cyclophilin A; n=8–9, with each condition performed in
triplicate).
doi:10.1371/journal.pone.0014476.g006
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